うつ病と脳卒中の罹患率と死亡率のリスク:メタ分析とシステマティックレビュー

An Pan¹, Qi Sun, Olivia I Okereke

¹Department of Nutrition, Harvard School of Public Health, 655 Huntington Ave, Boston, MA 02115, USA.

JAMA

|September 22, 2011

まとめ

うつ病は,致命的および不全性型を含む脳卒中のリスクを大幅に増加させます. このメタ解析は,うつ病と脳卒中の発生率と死亡率の上昇との間の一貫した関連性を確認しています.

科学分野:

神経学神経学とは
精神科医は精神病を患っている.
エピデミオロジーエピデミオロジー

背景:

既存の研究は,うつ病と脳卒中のリスクの増加との関連性を示唆しているが,結果は矛盾している.
うつ病は,公衆衛生に重大な影響を及ぼす一般的な精神的健康状態です.

研究の目的:

大人のうつ病と脳卒中リスクとの関連に関する将来性研究を体系的にレビューし,メタ分析する.
鬱病と脳卒中の罹患率と死亡率を関連付ける証拠の包括的な評価を提供するため.

主な方法:

MEDLINE,EMBASE,PsycINFOのデータベースで検索し,手動で検索した.
317,540人の参加者と8478人の脳卒中症例を含む28件の前向きなコホート研究が含まれています.
固定効果またはランダム効果モデルを使用して調整されたハザード比 (HRs) をプールし,出版バイアスを評価.

主要な成果:

合計脳卒中に対して1.45 (95%CI,1.29-1.63) の総合調整HRが観察されました.
致死性脳卒中 (HR=1.55) と不全性脳卒中 (HR=1.25) のリスクが高まっていることが判明しました.
絶対リスクの差は,うつ病による年間10万人あたりの脳卒中の合計106例の増加を示した.

結論:

うつ病は,脳卒中の罹患率と死亡率のリスクの増加と有意に関連しています.
この発見は,脳卒中予防戦略において,うつ病に対処することの重要性を強調しています.

さらに関連する動画

12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.0K

06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.3K

関連する概念動画

01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

627

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

627

01:20

Actuarial Approach

384

The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...

384

01:24

Kaplan-Meier Approach

792

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...

792

01:20

Comparing the Survival Analysis of Two or More Groups

712

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...

712

01:11

Hazard Rate

525

The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...

525

01:12

Hazard Ratio

756

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...

756

関連する実験動画